SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 2

The Relationship Between Bevacizumab Treatment and Platelet, Mean Platelet Volume and Thromboembolic Events in Patients with Metastatic Colorectal Cancer

Hatice KARAGÖZ
Semiha URVAY
Pages
181–186
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Age, gender,comorbidity status, body mass index, smoking status and the type of chemotherapy combination were also enrolled.Results: At the 3rd month of the treatment, mean platelet volume levels were found to be increased in the total patientgroup from 8.98±0.16 to 9.28±0.14 and this was statistically significant (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Colorectal cancer (CRC), is one of the leading causes of mortality worldwide and is the second most commoncancer in developed countries.
📊
Key Findings & Data:Mean platelet volume is a parameter that measures the plateletsize and is defined as a marker of platelet reactivity.Methods: A total of 108 patients from medical oncology department of Acibadem Kayseri Hospital with metastaticcolorectal cancer and receiving first line combination treatment with bevacizumab were included in this study.
💡
Conclusion & Impact:Age, gender,comorbidity status, body mass index, smoking status and the type of chemotherapy combination were also enrolled.Results: At the 3rd month of the treatment, mean platelet volume levels were found to be increased in the total patientgroup from 8.98±0.16 to 9.28±0.14 and this was statistically significant (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Colorectal cancer (CRC), is one of the leading causes of mortality worldwide and is the second most commoncancer in developed countries. Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelialgrowth factor has been approved for use in combination chemotherapy for the first or second-line treatment ofpatients with metastatic colorectal cancer. The risk of arterial thromboembolism was found to be higher in the patientsreceived combination treatment with bevacizumab. Mean platelet volume is a parameter that measures the plateletsize and is defined as a marker of platelet reactivity.Methods: A total of 108 patients from medical oncology department of Acibadem Kayseri Hospital with metastaticcolorectal cancer and receiving first line combination treatment with bevacizumab were included in this study. Age, gender,comorbidity status, body mass index, smoking status and the type of chemotherapy combination were also enrolled.Results: At the 3rd month of the treatment, mean platelet volume levels were found to be increased in the total patientgroup from 8.98±0.16 to 9.28±0.14 and this was statistically significant (p

🔖

Cite This Article

KARAGÖZ, H., URVAY, S. (2022). The Relationship Between Bevacizumab Treatment and Platelet, Mean Platelet Volume and Thromboembolic Events in Patients with Metastatic Colorectal Cancer. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 2, 181–186. https://ajindex.com/articles/508665

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet 2005
  2. 153–65. [CrossRef ] 2. National Cancer Institute: SEER Cancer Statistics Review. 1975–2002. 3. Engstrom PF, Benson AB, Cooper HS: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 2.2006, November 15, 2005. 4. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004
  3. 2335–342. [CrossRef ] 5. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008
  4. 3523– 9. [CrossRef ] 6. Burger RA, Sill MW, Monk BJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007
  5. 5165–71. [CrossRef ] 7. Friedman HS, Prados MD,Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009
  6. 4733–40. [CrossRef ] 8. Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007
  7. 2103–11. [CrossRef ] 9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007
  8. 2666–76. [CrossRef ] 10. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004
  9. 2184–91. [CrossRef ] 11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006
  10. 2542–50. [CrossRef ] 12. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005
  11. 25–33. 13. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab. J Natl Cancer Inst 2007
  12. 1232–9. [CrossRef ] 14. Li JY, Li Y, Jiang Zheng, et al. Elevated Mean Platelet Volume is Associated with Presence of Colon Cancer. Asian Pac J Cancer Prev 2014